Immunome (NASDAQ:IMNM) CFO Sells $1,093,800.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett sold 60,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the sale, the chief financial officer owned 54,037 shares of the company’s stock, valued at $985,094.51. This trade represents a 52.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Max Rosett also recently made the following trade(s):

• On Thursday, April 2nd, Max Rosett sold 65,000 shares of Immunome stock. The stock was sold at an average price of $21.92, for a total value of $1,424,800.00.

Immunome Price Performance

IMNM opened at $18.74 on Friday. The business has a fifty day simple moving average of $21.44 and a 200 day simple moving average of $21.69. Immunome, Inc. has a 1 year low of $7.96 and a 1 year high of $27.65. The company has a market capitalization of $2.12 billion, a PE ratio of -7.87 and a beta of 2.04.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.12. Equities analysts anticipate that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Institutional Trading of Immunome

Hedge funds have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. increased its position in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after acquiring an additional 5,003,824 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Immunome by 23.4% during the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares during the period. Primecap Management Co. CA raised its position in Immunome by 55.2% during the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. State Street Corp raised its position in Immunome by 37.9% during the 4th quarter. State Street Corp now owns 3,868,000 shares of the company’s stock worth $83,085,000 after purchasing an additional 1,064,027 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Immunome by 8,659.2% during the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after buying an additional 2,823,144 shares during the period. 44.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Immunome in a research report on Friday, June 12th. Barclays assumed coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective on the stock. Stephens dropped their target price on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Immunome in a research report on Wednesday, May 13th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Immunome has an average rating of “Moderate Buy” and an average target price of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.